Seedcamp is Europe's seed fund, identifying and investing early in world-class founders attacking large, global markets and solving real problems using technology. The Seedcamp Nation includes over 400 startups building breakout businesses that change the way people live, interact and buy and includes publicly listed UiPath, Wise, and unicorns Revolut, Hopin, Sorare, Pleo, and wefox along with fast-growing businesses such as Grover, viz.ai and Ezra.  Seedcamp fast-tracks a founder's vision and creates value through immediate access to smart capital, a lifelong community of support and a global network built upon more than a decade's experience backing exceptional talent. Seedcamp fast-tracks a founder's vision and creates value through immediate access to smart capital, a lifelong community of support, and a global network built upon more than a decade's experience backing exceptional talent.

Seedcamp

University of Cambridge Enterprise, also known as Cambridge Enterprise Seed Funds, consisting of the Challenge Fund and the Venture Fund, is a resource for members of the University of Cambridge and the Babraham Institute. Investments are priced and structured competitively with other sources of early stage seed capital in order to encourage co-investment, follow-on funding and commercialisation of University of Cambridge and Babraham Institute inventions.

University of Cambridge Enterprise

Parkwalk is a London-based fund management firm.  Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009, anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth. Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow.                                                                                                                 In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Parkwalk Advisors

Episode1 Ventures is a London based venture capital fund set up to invest in early-stage technology companies based in the UK. It was created with a mixture of public and private money, including backing from a number of entrepreneurs including Alex Chesterman of Zoopla Property Group. It is one of the UK Government's Enterprise Capital Funds – set up to support fund managers who invest in small, high-growth businesses. The £12.5 million of private investment was matched with £25 million of public money. Episode 1 Ventures invests in seed and Series A rounds of up to £2m in software-driven businesses with the potential to transform industries. They’ve been entrepreneurs theirselves so provide a frank and fast approach to investing and they like to play a very hands-on supportive role in growing the businesses they back. They look for entrepreneurs with relevant experience ambitious to change their sector. They like to see that they can hire world-class talent and delegate to them effectively, and that they really know the customers and understand the problem. They also like entrepreneurs that are data-driven. But above all they like people with passion and ambition, that can execute at speed and overcome significant hurdles along the way. They are building a portfolio of companies that are using software technology to disrupt their chosen marketplaces. It is a diverse group across a range of industries, but with two common themes – a great founder and a big market.  They also like to invest once a company has launched their product and has some clients they can reference. Revenues are usually from zero to £50k per month when they first invest. They like to play an active role in helping the companies that they invest in, at least until their companies have secured one or more later financing rounds. They want to help entrepreneurs turn their early stage ventures into fast growing companies built to grow into significant and valuable entities.  They see every investment as a partnership. Indeed, they share their office with a number of portfolio companies so they work very closely with them.

Episode 1

January Ventures is a VC fund focused on angel/pre-seed in the US & Europe. We are replacing the friends & family round and re-writing the networks in venture. We invest early and opens doors for the visionary founders of the future. We believe the founders of the next decade will look fundamentally different: more female, more diverse and more distributed. Our firm is built on the principles of transparency and access, and we back founders based on their tenacity and ambition, not their pedigrees or who they know.  January Ventures was founded in 2018 and is based in Boston, MA and London, UK.

January Ventures

MMC Ventures is an investment firm that invests in technology companies at Seed and Series A. MMC commits to a deep understanding of each company’s underlying technology and business model to help make better decisions and be more effective partners. Transformative technology companies MMC has backed to date include Gousto, Interactive Investor, Copper, Signal AI, Synthesia, Peak and more.

MMC Ventures

Synetro is an active seed and early stage investor in web based technology and business services companies. It also operates a private equity business focused on acquiring and turning around software, business services and manufacturing companies.

Synetro Group

Plural Platform is an early-stage venture capital firm.

Plural Platform

Sano Genetics

Sano Genetics is a health technology company that focuses on personalized medicine and genetics. They aim to empower individuals to contribute their genetic and health data for research purposes, with the goal of advancing scientific understanding and personalized approaches to healthcare. Sano Genetics often operates within the context of genetic research studies and projects, allowing participants to share their genetic information to contribute to the broader field of medical research

Sano Genetics provides an online platform that combines genetic testing, recruitment, and long-term patient-clinician engagement to assist in clinical trials. The platform helps to connect patients across four countries, UK, US, Australia, and Canada, with pharmaceutical and biotechnology companies conducting clinical trials through advertising initiatives in social media and via healthcare providers. Post-patient recruitment, the platform additionally assists with patient communication, facilitating genetic and other biomarker testing, returning results, and supporting patients with genetic counseling.

Incorporating technology to improve efficiency and success rate of clinical trials

Clinical Trial Technology

Sano Genetics lights the way to fresh hope for MND sufferers

Sano Genetics provides an online platform that combines genetic testing, recruitment, and long-term patient-clinician engagement to assist in clinical trials. The platform helps to connect patients across four countries, UK, US, Australia, and Canada, with pharmaceutical and biotechnology companies conducting clinical trials through advertising initiatives in social media and via healthcare providers. Post-patient recruitment, the platform additionally assists with patient communication, facilitating genetic and other biomarker testing, returning results, and supporting patients with genetic counseling.In January 2024, the company noted it had recorded a 5x YoY growth in ARR in 2023 and doubled its staff to 62. Key customers and partnerships As of January 2024, the company noted that it has initiated partnerships with four of the top 20 pharmaceutical companies.In May 2022, the company partnered with PrecisionLife to accelerate understanding of long Covid-19 and help identify new treatments. Through the partnership, Sano Genetics’ data from 3,000 UK adults suffering from long Covid-19 symptoms were expected to be analyzed using PrecisionLife’s proprietary combinatorial analytics platform to identify risk-factors and potential drug targets.Funding and financials In January 2024, Sano raised USD 11.4 million in a funding round led by Plural, with participation from existing investors. The funding was set aside to cater to the growing demand for Sano Genetics' products, incorporate AI more extensively, and expand its footprint in additional countries.

Headquartered in Amsterdam, Castor is a cloud-based e-clinical data platform that can be used for a range of tasks and processes during a clinical trial. It offers four solutions: 1) electronic data capture (EDC) to capture and process data from multiple sources including researchers, 2) electronic patient-reported outcomes (ePRO) to collect and manage patient-reported data on a centralized platform, 3) e-consent - to enable patients to be recruited, screened, and enrolled remotely, and 4) a decentralized clinical trials (DCT) platform to assist operators with managing DCT technologies and devices through a central platform. The company’s solutions are targeted at industries like biotech and pharma, diagnostics, and clinical research organizations. Its solutions are built in line with industry-standard compliance and data protection standards including HIPAA, GDPR, and ISO 27001.Castor aimed to collect enough clinical trial research data to enable the reuse of data for AI-driven clinical trials, which would lower the costs of operating clinical trials and reduce the time taken to bring new drugs to market.Key customers and partnershipsAs of June 2024, the company had supported 14,000+ studies and 6 million patients through clinical trials across 90+ countries, since launching in 2007. In terms of therapeutic areas, Castor had supported a range of different areas, including oncology, cardiovascular diseases, and diabetes. The company had been engaged by 500+ organizations, including the World Health Organization, Click Therapeutics, and Stryker. It was the first to incorporate machine learning into its system for the identification of Covid-19 patients. The company offered free access to its system for Covid-19 research projects, with over 200 projects using the platform as of June 2022. In February 2024, the company partnered with Microsoft to use Microsoft Azure to bring modern AI to clinical trials. The feature was released to help Castor users develop their studies faster by simplifying complex tasks in the study build process. The company additionally noted that it was planning to release its first in a line of Practical AI features to all its users in public Beta. Funding and financialsThe company raised USD 45 million in Series B funding in July 2021, led by Eight Roads Ventures and F-Prime Capital. The funds were earmarked for product development, interoperability with partner systems, and market research on decentralized trials. The company had a headcount of 150 at the time of the Series B and was planning to expand to 200 by the end of 2021.

Castor

Florence Healthcare offers a platform for clinical trial management. It has four key components: 1) SiteLink to start-up and monitor remote clinical sites, 2) eBinders to digitize and store research binders, 3) eConsent to simplify and digitize the consent process, and 4) Electronic Trial Master File to digitize the storage and transfer of files between sites and research sponsors. The platform is compliant with standard industry requirements including HIPAA, 21 C.F.R Part 11, ICF/GCP, and GDPR.Key customers and partnershipsAs of June 2024, Florence supported over 18,000 research sites, across 55+ countries, with key customers including Pfizer. The usage of the company’s software tripled in 2020, driven by an industry shift toward digitalization as a result of the Covid-19 pandemic. In February 2022, the company was ranked as the best clinical trial platform out of a group of 190 for ease of setup, ease of use, and customer support.Florence partnered with Greenphire, a company focusing on patient convenience and financial management for clinical trials, in Janauary 2024. Through the partnership, Florence's platform will be integrated with Greenphire's to improve payment systems within clinical trials. Benefits of the partnership included reduced manual work for sites, faster payments, and better visibility of site activity for sponsors and Contract Research Organizations (CROs). Funding and financialsThe company raised USD 80 million in Series C funding in May 2021 led by Insight Partners. The proceeds were to be used to scale up its sales and marketing teams and improve the value proposition of the platform by reducing the time required by customers to implement and manage clinical trials.

Florence Healthcare

Huma is a UK- and US-based clinical trial tech startup that provides a digital platform to manage clinical trials, including decentralized clinical trials. The platform can be used throughout the clinical trial process, including patient recruitment, screening, electronic consent, clinical outcome assessments, patient-reported outcomes, and telemedicine. The platform is built up to industry standards in data privacy and security, including ISO 27001, 21 C.F.R. Part 11, and TxP.In June 2023, the company <a href="https://sp-edge.com/updates/19352">received FDA 510(k) Class II FDA clearance </a>for its configurable disease-agnostic platform, including its cardiovascular risk score algorithm. The company received this FDA clearance in partnership with Health Canada and it allows Huma's platform to be used to monitor patients of all ages with any condition, including pediatrics and pregnancy. The Class II clearance also enables the platform to host algorithms that provide automated AI-driven data analytics for diagnosis, screening, clinical decision-making, predictions on health outcomes, and recommendations on dosage.In July 2024, the company was <a href="https://sp-edge.com/updates/31552">estimated to be valued at nearly USD 1 billion</a> when it secured a Series D investment of USD 80 million. Key customers and partnershipsSome of the key partners working with Huma include AstraZeneca, Johnson &amp; Johnson, Bayer, Stanford University, and the University of Cambridge. As of July 2024, the platform supported 3,000+ hospitals and clinics, screened over 35 million individuals, and had 1.8 million active users across 70 countries. Huma was awarded the 2021 Prix Galien Award, which is widely considered the “Nobel Prize” for pharmaceuticals and life sciences.The company announced a partnership with Xyla Elective Care in June 2022, to provide support to the UK’s National Health Service in delivering and managing virtual wards.

Huma

Based in California and founded in 2015, Medable is a digital clinical trial management platform with a range of modules for different processes. These modules include a decentralized clinical trial platform to support decentralized trials using remote tools for data gathering, monitoring, televisits, and consent; digital patient screening to screen patients remotely and at scale; e-consent to enable patients to digitally consent for clinical trials; electronic clinical outcome assessments; and patient-reported outcomes to document data in real time and provide easy access for researchers. It also includes remote patient monitoring to make it easy for patients to record and share data with clinical research teams.Medable operates on a SaaS business model, with customers having the option of selecting and deploying only the modules required as part of their uniquely customized solution.In August 2024, Medable launched 'Medable Studio', an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisits, and sensors) into clinical trials. The no-code suite aimed to simplify the complex eCOA launch process, offering biopharmaceutical companies greater control and transparency. Medable Studio includesda point-and-click builder for creating assessments and instruments, a visual schedule of assessments builder, a translation workbench, and a content library. The platform enabled users to rapidly build and launch complex clinical trials, with the ability to create protocol-fit study designs in hours instead of months.As of June 2024, the company offered its platforms across 60 countries and was accessible by over 120 companies. The company’s platform is compliant with industry standards, including HIPAA, FDA’s 21 CFR Part 11, and GDPR.Key customers and partnershipsAs of June 2024, Medable claimed to work with 14 out of the top 20 pharmaceutical companies, in addition to working with a range of partners, including Cognizant, Accenture, Oracle, and PwC.In February 2022, the company announced a Medable Partner Network, which brought together a range of partners across different types. This included direct-to-patient, service, data, technology, and site partners. The objective of this partnership network is to speed up the innovation process and deployment of the platform at clinical sites, creating value for Medable’s customers.In September 2022, the company announced a four year agreement with GlaxoSmithKline to use Medable’s platform for clinical trials across multiple products. Financial terms of the agreement were not disclosed.In October 2023, the company partnered with Pluto Health, a healthcare coordination company, to enhance the clinical trial experience for participants and improve data collection during trials. Through the partnership, the companies aimed to connect patients to the right medical resources including access to clinical trials and home delivery of medication. Pluto Health's platform would collect participants’ health information and create personalized care plans, while Medable would offer features such as patient identification and remote patient monitoring. The partnership also aimed to improve data quality and facilitate long-term follow-up with patients post-trial.In May 2024, Medable partnered with Masimo, a medical technology provider, to incorporate new wearable devices in clinical research. Medable announced it would include the MightySat Rx pulse oximeter by Masimo in its platform for various major clinical trials, particularly in lung and breast cancer research.

Medable

Headquartered in New York, Obvio Health provides a full service for clients, supporting them throughout the clinical trial process from the design and recruitment stages to outcome measurement and reporting. In addition to its technological platform, the company provides professional services to execute clinical trials using its in-house clinical operations team. The platform caters to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, gi, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001.According to the company, its platform was designed from the ground up to cater to digital trials run by virtual clinical teams, which resulted in faster patient recruitment (three months for Obvio compared to 12 months for physical site trials). In January 2022, the company launched an augmented electronic patient-reported outcome (augmented ePRO) module, which incorporates AI and manual scoring by experts/clinicians. The company claims this improves the accuracy and quality of data collected.In April 2024, the ObvioHealth launched ObvioGo 2.0, an enhanced platform and mobile application designed to meet the unique needs of trial sites and sponsors. The upgraded platform allows the combination of hybrid and virtual trial designs within one study. It includes features such as the ability to create site-specific workflows, integration with other clinical systems, and a streamlined translation process. Additional features include a built-in virtual assistance team, COACH, for trial tasks support and a patient identifier tool for patient registration and data correlation.As of June 2024, the platform catered to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, GI, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001. Key customers and partnershipsAs of June 2024, Obvio Health’s client base included companies like GlaxoSmithKline, Pfizer, Bayer, Danone, and General Mills. As of June 2024, the company’s operations were spread over 28 countries and had supported obtaining consent from 40,000+ patients across 40 clinical trials since its launch.In March 2022, Obvio partnered with Renovia to conduct the first fully virtual trial in urogynaecology, based on Renovia’s Leva device. The device helped patients with performing kegel exercises more effectively, in addition to monitoring compliance over the trial period.In November 2023, Obvio then partnered with Chemist Warehouse, the largest retail pharmacy chain in Australia, to improve the reach and efficiency of clinical trials. Through the partnership, Chemist Warehouse agreed to promote ObvioHealth-managed trials to its customers in Australia, using both offline and online channels. Additionally, ObvioHealth agreed to utilize Chemist Warehouse's Telehealth services for studies that require clinician assessments. The collaboration aimed to increase the awareness and convenience of clinical trials, addressing two major hurdles in participant recruitment. The long-term goal of the partnership was to expedite the introduction of innovative therapies to the market more efficiently and economically. Funding and financialsThe company raised USD 31 million of Series B funding in June 2021 led by Dedalus Group and Novotech Health. The investment was primarily strategic, with Obvio benefiting from its Dedalus partnership in terms of European clinical trial compliance, while it became Novotech Health’s preferred virtual clinical trial provider.

Obvio Health

Companies offering data and workflow management platforms and solutions to assist with the operational management of a clinical trial, including site management, monitoring processes in terms of risk and documentation, and payment automation.

Companies using remote patient monitoring tools and other connectivity solutions to enable remote collection of patient data and monitoring and run trials virtually, without requiring the patient to be physically present in the clinical trial site.

Companies that offer workflow management platforms that are used to manage logistics tasks and processes for clinical trials, primarily the randomization of assigning patients in a clinical trial and automation of logistics workflows based on clinical trial data.

This is the use of software, incorporating AI and Machine Learning technology to improve the matching process of patients with suitable clinical trials.

Companies that offer software solutions for identifying and evaluating potential trial sites, along with documentation and workflow management systems to complete the processes before launching, including electronic patient consent and other required regulatory tasks.

Includes companies that provide digital data management platforms to collect and store patient reported outcome data. These platforms are also incorporating data analytics to help understand the results and identify trends and patterns. Additionally, the platforms are enabling connectivity with remote monitoring devices, including Medical Internet of Things.

Companies that provide software tools that help with the design of clinical trials, including identifying protocol violations, collecting participant input on potential design ideas for the trial, and crowdsourcing of protocol ideas for clinical trials.

Most CTT platforms are offered on a B2B basis to companies carrying out clinical trials

Startups in this hub use IoT to support report patient monitoring and data gathering

Offers digital platforms that accelerate clinical trials and evaluations

AI/ML algorithms can be used to automate the analysis of patient data

Startups in this hub seek to improve clinical trial diversity by including underrepresented communities

<div>
 
 Sano Genetics, a firm offering a patient recruitment platform, has gathered USD 11.4 million in a funding round led by Plural, raising their total funding to USD 22 million. The firm plans to use the funding for product demand, AI integration, and expansion into new countries.
 The platform is already operational in the UK, the US, Australia, and Canada, connecting patients with pharmaceutical and biotech companies running clinical trials. Besides, the platform also aids in patient communication and provides support for genetic counseling.
 
</div>

Sano Genetics

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless